The Epidemiology of Osteosarcoma, Cancer Treat Res, vol.152, pp.3-13, 2009. ,
DOI : 10.1007/978-1-4419-0284-9_1
Osteosarcoma, American Journal of Clinical Pathology, vol.125, issue.4, pp.555-581, 2006. ,
DOI : 10.1309/UC6KQHLD9LV2KENN
Recent advances in osteosarcoma, Current Opinion in Pharmacology, vol.16, pp.15-23, 2014. ,
DOI : 10.1016/j.coph.2014.02.002
Evidence for the osteosarcoma stem cell, Current Orthopaedic Practice, vol.22, issue.4, pp.322-326, 2011. ,
DOI : 10.1097/BCO.0b013e318221aee8
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols, Journal of Clinical Oncology, vol.20, issue.3, pp.776-790, 2002. ,
DOI : 10.1200/JCO.2002.20.3.776
Prognostic factors in osteosarcoma: a critical review., Journal of Clinical Oncology, vol.12, issue.2, pp.423-431, 1994. ,
DOI : 10.1200/JCO.1994.12.2.423
Osteosarcoma: a meta-analysis and review of the literature, Am J OrthopBelle Mead NJ), vol.44, pp.547-553, 2015. ,
Osteosarcoma treatment ??? Where do we stand? A state of the art review, Cancer Treatment Reviews, vol.40, issue.4, pp.523-532, 2014. ,
DOI : 10.1016/j.ctrv.2013.11.006
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery, Cancer, vol.36, issue.6, pp.2163-2177, 1979. ,
DOI : 10.1007/978-3-642-95227-2_24
Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review, Clin Sarcoma Res, vol.5, p.17, 2015. ,
Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor, Cancer, vol.153, issue.7, pp.1515-1521, 1985. ,
DOI : 10.1148/radiology.149.3.6580673
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment, Cancer Cell, vol.21, issue.3, pp.309-322, 2012. ,
DOI : 10.1016/j.ccr.2012.02.022
Bone microenvironment signals in osteosarcoma development, Cellular and Molecular Life Sciences, vol.128, issue.2, pp.3097-3113, 2015. ,
DOI : 10.1002/ijc.25331
Influence of tumour micro-environment heterogeneity on therapeutic response, Nature, vol.37, issue.7467, pp.346-354, 2013. ,
DOI : 10.1038/ng1596
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer, Nature Medicine, vol.57, issue.1, pp.68-74, 2009. ,
DOI : 10.1186/bcr1608
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance, Clinical Cancer Research, vol.14, issue.9, pp.2519-2526, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-2223
Fusion between cancer cells and myofibroblasts is involved in osteosarcoma, Oncology Letters, vol.2, issue.6, pp.1083-1087, 2011. ,
DOI : 10.3892/ol.2011.363
Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer, Oncotarget, vol.6, issue.15, pp.13803-13821, 2015. ,
DOI : 10.18632/oncotarget.3144
Defining normoxia, physoxia and hypoxia in tumours???implications for treatment response, The British Journal of Radiology, vol.61, issue.1035, p.20130676, 2014. ,
DOI : 10.1186/1471-2407-12-496
Drug Resistance and the Solid Tumor Microenvironment, JNCI Journal of the National Cancer Institute, vol.99, issue.19, pp.1441-1454, 2007. ,
DOI : 10.1093/jnci/djm135
Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma, In Vivo, vol.16, pp.223-228, 2002. ,
Determination of subcutaneous tumor size in athymic (nude) mice, Cancer Chemotherapy and Pharmacology, vol.45, issue.3, pp.148-154, 1989. ,
DOI : 10.1038/bjc.1985.57
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67, Breast Cancer Research, vol.8, issue.4, p.56, 2010. ,
DOI : 10.1038/nm791
Basic Image Analysis and Manipulation in ImageJ, Curr Protoc Mol Biol, vol.4, 2013. ,
DOI : 10.1074/mcp.M500279-MCP200
A preclinical model for experimental chemotherapy of human head and neck cancer, International Journal of Oncology, vol.18, pp.1145-1154, 2001. ,
DOI : 10.3892/ijo.18.6.1145
Treatment with resveratrol attenuates sublesional bone loss in spinal cord-injured rats, British Journal of Pharmacology, vol.315, issue.Suppl. 1, pp.796-806, 2013. ,
DOI : 10.1016/j.yexcr.2009.07.030
URL : http://onlinelibrary.wiley.com/doi/10.1111/bph.12301/pdf
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo, Proceedings of the National Academy of Sciences, vol.108, issue.5, pp.1850-1855, 2011. ,
DOI : 10.1517/17425247.5.3.309
Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice, Journal of Bone and Mineral Research, vol.14, issue.10, pp.2118-2129, 2012. ,
DOI : 10.1158/1078-0432.CCR-07-2223
The effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model, Anticancer Res, vol.32, pp.3791-3798, 2012. ,
Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.16, pp.1167-1178, 2008. ,
DOI : 10.1093/jnci/djn240
Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up, Ann Oncol, vol.20, issue.4, pp.137-139, 2009. ,
DOI : 10.1093/annonc/mdn102
URL : https://academic.oup.com/annonc/article-pdf/19/suppl_2/ii94/726991/mdn102.pdf
Chemotherapy for osteosarcoma, Oncologie, vol.2, issue.Suppl2, pp.164-169, 2007. ,
DOI : 10.1056/NEJM198606193142502
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Research, vol.41, issue.D1, pp.955-961, 2013. ,
DOI : 10.1093/nar/gks1111
A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis, European Journal of Cancer, vol.49, issue.9, pp.2253-2263, 2013. ,
DOI : 10.1016/j.ejca.2013.02.020
Quantifying intra-osseous growth of osteosarcoma in a murine model with radiographic analysis, Journal of Orthopaedic Research, vol.48, issue.12, pp.1957-1962, 2011. ,
DOI : 10.1016/j.bone.2010.05.033
Preclinical mouse models of osteosarcoma, BoneKEy Reports, vol.4, p.670, 2015. ,
DOI : 10.1038/bonekey.2015.37
A tumor cord model for Doxorubicin delivery and dose optimization in solid tumors, Theoretical Biology and Medical Modelling, vol.6, issue.1, p.16, 2009. ,
DOI : 10.1186/1742-4682-6-16
Doxorubicin gradients in human breast cancer, Clin Cancer Res, vol.5, pp.1703-1707, 1999. ,
The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors, Clinical Cancer Research, vol.11, issue.24, pp.8782-8788, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-1664
Exploiting tumour hypoxia in cancer treatment, Nature Reviews Cancer, vol.56, issue.6, pp.437-447, 2004. ,
DOI : 10.1016/0360-3016(96)00132-0
Drug penetration in solid tumours, Nature Reviews Cancer, vol.23, issue.1, pp.583-592, 2006. ,
DOI : 10.1177/002215549704500909
Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity, Molecular Cancer Therapeutics, vol.7, issue.7, pp.1961-1973, 2008. ,
DOI : 10.1158/1535-7163.MCT-08-0198
URL : http://mct.aacrjournals.org/content/molcanther/7/7/1961.full.pdf
Thérapie cellulaire de l'angiogenèse tumorale: évaluation par imagerie morphologique et fonctionnelle en IRM et vidéomicroscopie de fluorescence, 2011. ,
Enhanced survival and engraftment of transplanted stem cells using growth factor sequestering hydrogels, Biomaterials, vol.47, pp.1-12, 2015. ,
DOI : 10.1016/j.biomaterials.2014.12.043
Clinical aspects of drug delivery to tumors, Journal of Controlled Release, vol.78, issue.1-3, pp.81-95, 2002. ,
DOI : 10.1016/S0168-3659(01)00488-6
A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level, The EMBO Journal, vol.35, issue.1, pp.102-113, 2016. ,
DOI : 10.15252/embj.201592775